Back to Search
Start Over
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
- Source :
- The Lancet; January 2016, Vol. 387 Issue: 10013 p40-52, 13p
- Publication Year :
- 2016
-
Abstract
- Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are requisite drivers of atopic dermatitis, evidenced by marked improvement after treatment with dupilumab, a fully-human monoclonal antibody that blocks both pathways. We aimed to assess the efficacy and safety of several dose regimens of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments.
Details
- Language :
- English
- ISSN :
- 01406736 and 1474547X
- Volume :
- 387
- Issue :
- 10013
- Database :
- Supplemental Index
- Journal :
- The Lancet
- Publication Type :
- Periodical
- Accession number :
- ejs36981031
- Full Text :
- https://doi.org/10.1016/S0140-6736(15)00388-8